Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NX-210c by Axoltis Pharma for Alzheimer's Disease: Likelihood of Approval
NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...
NX-210c by Axoltis Pharma for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS). According...
NX-210c by Axoltis Pharma for Parkinson's Disease: Likelihood of Approval
NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase...
NX-210c by Axoltis Pharma for Amyotrophic Lateral Sclerosis: Likelihood of Approval
NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData,...